Tianjin Zhongxin Pharmaceutical Group Corporation Limited provided earnings guidance for the year ending December 31, 2012. For the year, the company expects that the net profit of the group for fiscal year 2012 will increase by approximately 70% to 90% over the previous corresponding period based on the Accounting Standards for Business Enterprises of the People's Republic of China. The net profit of the Group for fiscal year 2012 is expected to increase by approximately 70% to 90% over the previous corresponding period due to the following reasons: gain on disposal of the Company's subsidiary, being Tianjin Central Pharmaceutical Co.

Ltd.; increase in the return on investment from the Company's associated company, being Sino-American Tianjin SmithKline & French Lab. Ltd. increase in operating profits from the Group's main business.